Global Autologous Cell Therapy Market Size Study, by Application (Cancer, Neurodegenerative Disorders, Cardiovascular Disorders, Autoimmune Disorders, Orthopedics, Wound Healing, Others), by Source (Bone Marrow, Peripheral Blood, Adipose Tissue, Others),

Global Autologous Cell Therapy Market Size Study, by Application (Cancer, Neurodegenerative Disorders, Cardiovascular Disorders, Autoimmune Disorders, Orthopedics, Wound Healing, Others), by Source (Bone Marrow, Peripheral Blood, Adipose Tissue, Others), by End-Use (Hospitals, Academics & Research, Others), and Regional Forecasts 2022-2032

The Global Autologous Cell Therapy Market is valued approximately at USD 4.32 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 22.20% over the forecast period 2024-2030. Autologous cell therapy involves using a patient's cells, typically derived from tissues like bone marrow or blood, to treat various medical conditions. These cells are harvested from the patient, processed to isolate specific types of cells (such as stem cells or immune cells), and then reintroduced into the patient's body. Autologous cell therapy is used in treatments for conditions such as cancer, autoimmune diseases, and certain genetic disorders, aiming to harness the body's own regenerative or immune capabilities for therapeutic benefit. The Global Autologous Cell Therapy Market is experiencing robust growth driven by several key factors. The rise in the geriatric population and the increasing prevalence of chronic diseases such as cancer and neurodegenerative disorders are significantly driving the market growth.

The rise in the geriatric population and the increasing prevalence of chronic diseases such as cancer and neurodegenerative disorders are significant contributors. The aging population leads to a higher incidence of age-related ailments, necessitating advanced treatment options. Simultaneously, the growing number of patients diagnosed with chronic conditions highlights the urgent need for innovative therapies, making autologous cell therapy a critical area of development and investment in the healthcare sector. Moreover, the market is witnessing technological advancements in cell isolation and expansion, making these therapies more accessible and cost-effective. For instance, in March 2024, the FDA approved Breyanzi by Bristol Myers Squibb for adults with CLL or SLL that is relapsed or refractory. This CAR-T cell therapy is given as a one-time infusion. The clinical trials and market expansions of key players are enhancing the market dynamics. Moreover, increasing investment and research in autologous cell therapies and adoption of personalized medicine are creating new opportunities to the market growth. However, the high cost of autologous cell therapy, Stringent Regulatory Requirements are hindering the market growth during the projected period 2024-2032.

Key regions considered for the global Autologous Cell Therapy market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2023, North America dominated the market, driven by the presence of major market players and advanced healthcare infrastructure. The U.S. held the largest share in the North American region and is expected to grow rapidly over the forecast period due to FDA approvals and increasing investments. Europe also shows significant potential, with supportive regulatory environments and substantial funding for research. The Asia-Pacific region is anticipated to witness the fastest growth due to the rising burden of diseases and strong research activities in autologous cell therapies.

Major market players included in this report are:

BrainStorm Cell Therapeutics

Holostem Terapie Avanzate S.R.L

Pharmicell Co. Inc

Opexa Therapeutics

Caladrius Biosciences Inc

U.S. Stem Cell Inc

Lonza Group AG

Bristol Myers Squibb

Novartis AG

The detailed segments and sub-segment of the market are explained below:

By Application:

Cancer

Neurodegenerative Disorders

Cardiovascular Disorders

Autoimmune Disorders

Orthopedics

Wound Healing

Others

By Source:

Bone Marrow

Peripheral Blood

Adipose Tissue

Others

By End-Use:

Hospitals

Academics & Research

Others

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Middle East & Africa

Saudi Arabia

South Africa

RoMEA

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with Country level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.